甲状腺疾患治療市場- 世界の産業規模、シェア、動向、機会、予測、適応症別、投与経路別、流通チャネル別、地域別、競合別、2020～2030年

甲状腺疾患治療の世界市場規模は2024年に27億1,000万米ドルとなり、予測期間には34億3,000万米ドルに達すると予測され、2030年までのCAGRは3.98%です。

世界の甲状腺疾患治療市場は、甲状腺機能低下症、甲状腺機能亢進症、甲状腺結節、甲状腺がんを含む甲状腺関連疾患の有病率の上昇により、大きな成長を遂げています。甲状腺の健康に関する意識の高まり、早期診断、高度な治療オプションの利用可能性は、市場拡大に寄与する主な要因です。甲状腺疾患に罹患しやすい老年人口の増加が、効果的な治療ソリューションへの需要をさらに高めています。製薬会社やヘルスケアプロバイダーは、甲状腺疾患の管理に広く使用されているレボチロキシン、メチマゾール、放射性ヨード療法などの医薬品へのアクセスを改善することに注力しています。遠隔医療や遠隔監視を含むデジタルヘルスソリューションの統合も、タイムリーな診察と個別化された治療計画の確保による患者ケアの強化に重要な役割を果たしています。

ヘルスケア支出の増加とバイオテクノロジーの進歩により、甲状腺疾患の新規治療アプローチの開発が加速しています。併用療法、標的生物学的製剤、個別化医療の出現は、治療成績と患者の経験に革命をもたらしています。ホルモン補充療法や、ラジオ波焼灼療法や超音波ガイド下治療などの低侵襲手技の採用が増加しており、治療の選択肢が拡大しています。高感度アッセイや画像技術を含む診断ツールの革新は、早期発見とより良い疾患管理を可能にしています。製薬企業による研究開発投資の増加は新薬の発見を促進し、今後数年間の市場拡大を牽引すると予想されます。

市場は、高額な治療費、新興国市場における先進治療へのアクセス制限、特定の甲状腺治療薬の長期的な安全性と有効性に関する懸念といった課題に直面しています。甲状腺疾患は複雑で、しばしば生涯にわたる管理が必要となるため、患者とヘルスケア提供者の双方に困難をもたらします。新薬や治療法に対する規制当局の厳しい承認プロセスは、市場参入を遅らせ、革新的な治療法の利用を制限する可能性があります。心血管合併症や骨密度低下など、甲状腺ホルモン補充療法に伴う副作用は、依然として患者や医療関係者の間で懸念されています。このような課題にもかかわらず、精密医療への注目の高まり、ヘルスケア・インフラの拡大、製薬会社と研究機関の協力関係の拡大が、市場成長の機会を生み出しています。また、橋本甲状腺炎やバセドウ病などの自己免疫性甲状腺疾患の有病率が上昇していることも、先進的な免疫療法や生物学的治療に対する需要を促進しており、甲状腺疾患管理の状況をさらに再構築する可能性があります。

主な市場促進要因

技術の進歩と革新的治療法

主な市場課題

ヘルスケアサービスへのアクセス制限

主要市場動向

個別化医療と標的治療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の甲状腺疾患治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症別（甲状腺機能低下症、甲状腺機能亢進症）
  • 投与経路別（経口、静脈内、その他）
  • 流通チャネル別（卸売業者/販売業者、小売チェーン、オンライン流通、その他）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米の甲状腺疾患治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の甲状腺疾患治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の甲状腺疾患治療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の甲状腺疾患治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの甲状腺疾患治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（ある場合）
• 製品の発売（ある場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Abbvie Inc.
• Amgen Inc.
• GSK Plc
• Merck KGaA
• Viatris Inc.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Elexis Inc.
• IBSA Pharma（IBSA Group）

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Thyroid Gland Disorder Treatment Market was valued at USD 2.71 Billion in 2024 and is expected to reach USD 3.43 Billion in the forecast period with a CAGR of 3.98% through 2030. The Global Thyroid Gland Disorder Treatment Market is experiencing significant growth due to the rising prevalence of thyroid-related conditions, including hypothyroidism, hyperthyroidism, thyroid nodules, and thyroid cancer. Increasing awareness about thyroid health, early diagnosis, and the availability of advanced treatment options are key factors contributing to market expansion. The growing geriatric population, which is more susceptible to thyroid disorders, is further fueling demand for effective treatment solutions. Pharmaceutical companies and healthcare providers are focusing on improving access to medications such as levothyroxine, methimazole, and radioactive iodine therapy, which are widely used for managing thyroid conditions. The integration of digital health solutions, including telemedicine and remote monitoring, is also playing a crucial role in enhancing patient care by ensuring timely consultations and personalized treatment plans.

Rising healthcare expenditure and advancements in biotechnology are accelerating the development of novel treatment approaches for thyroid disorders. The emergence of combination therapies, targeted biologics, and personalized medicine is revolutionizing treatment outcomes and patient experiences. The growing adoption of hormone replacement therapy and minimally invasive procedures such as radiofrequency ablation and ultrasound-guided treatments is expanding treatment options. Innovations in diagnostic tools, including high-sensitivity assays and imaging techniques, are enabling early detection and better disease management. Increased investment in research and development by pharmaceutical companies is fostering the discovery of new drugs, which is expected to drive market expansion in the coming years.

The market faces challenges such as high treatment costs, limited accessibility to advanced therapies in developing regions, and concerns related to the long-term safety and efficacy of certain thyroid medications. The complexity of thyroid disorders, which often require lifelong management, poses difficulties for both patients and healthcare providers. Stringent regulatory approval processes for new drugs and therapies can delay market entry and limit the availability of innovative treatment options. Side effects associated with thyroid hormone replacement therapies, including cardiovascular complications and bone density loss, remain concerns among patients and medical professionals. Despite these challenges, the increasing focus on precision medicine, expansion of healthcare infrastructure, and growing collaborations between pharmaceutical companies and research institutions are creating opportunities for market growth. The rising prevalence of autoimmune thyroid diseases, such as Hashimoto's thyroiditis and Graves' disease, is also driving demand for advanced immunotherapies and biologic treatments, which could further reshape the landscape of thyroid disorder management.

Key Market Drivers

Technological Advancements and Innovative Therapies

Technological advancements and innovative therapies are significantly transforming the global thyroid gland disorder treatment market. The development of novel drug formulations, improved diagnostic tools, and advanced treatment modalities is enhancing the accuracy, efficiency, and effectiveness of thyroid disorder management. Precision medicine plays a crucial role by enabling personalized treatment approaches tailored to individual patient profiles, considering genetic, environmental, and lifestyle factors that influence thyroid function. The introduction of biologics and targeted therapies is expanding treatment options beyond traditional hormone replacement therapies, offering more effective solutions for conditions such as hypothyroidism, hyperthyroidism, and thyroid-related autoimmune disorders.

Advancements in diagnostic technologies, including high-resolution imaging, biomarker-based blood tests, and AI-powered diagnostic tools, are enabling early detection and accurate assessment of thyroid disorders. These technologies facilitate timely intervention, reducing the risk of complications associated with delayed diagnosis. The emergence of non-invasive and minimally invasive treatment options, such as radiofrequency ablation and ultrasound-guided therapies, provides patients with alternatives to surgical interventions, minimizing recovery time and associated risks. Innovations in drug delivery systems, such as extended-release formulations and novel oral delivery mechanisms, are improving patient adherence by reducing dosing frequency and enhancing drug stability.

Continuous research and development efforts are leading to groundbreaking discoveries in thyroid disorder treatment, including the exploration of regenerative medicine and gene therapy. These approaches have the potential to restore normal thyroid function by addressing the underlying causes of thyroid dysfunction rather than merely managing symptoms. Increased investment in biopharmaceutical research is accelerating the development of next-generation thyroid disorder treatments, driving market growth. The integration of digital health solutions, such as remote patient monitoring and AI-driven treatment recommendations, is further optimizing disease management, enhancing patient engagement, and supporting healthcare providers in delivering more effective and personalized care.

Key Market Challenges

Limited Access to Healthcare Services

Limited access to healthcare services poses a significant challenge to the global thyroid gland disorder treatment market, particularly in low- and middle-income countries. Many individuals suffering from thyroid disorders, such as hypothyroidism, hyperthyroidism, and thyroid nodules, struggle to receive timely diagnosis and appropriate treatment due to inadequate healthcare infrastructure. A shortage of endocrinologists and specialized healthcare professionals further limits patient access to expert consultations, leading to delays in disease management. In rural and underserved regions, medical facilities often lack the necessary diagnostic tools, such as thyroid function tests and imaging technologies, making early detection difficult. Patients in these areas may remain undiagnosed for extended periods, exacerbating symptoms and increasing the risk of severe complications such as cardiovascular diseases, osteoporosis, and metabolic disorders.

High out-of-pocket costs for consultations, diagnostic tests, and long-term medication contribute to the challenge, particularly in regions with limited healthcare insurance coverage. Many thyroid disorders require lifelong treatment, and financial constraints can lead patients to discontinue therapy, resulting in uncontrolled disease progression. The availability of essential thyroid medications, including levothyroxine and antithyroid drugs, is inconsistent in some markets due to supply chain disruptions and regulatory barriers.

Limited public awareness about thyroid disorders also hinders early diagnosis and treatment adherence. Many individuals remain unaware of common symptoms, leading to misdiagnosis or underreporting of cases. Strengthening healthcare infrastructure, expanding insurance coverage, and promoting educational initiatives are essential to overcoming these barriers and improving access to thyroid disorder treatments.

Key Market Trends

Personalized Medicine and Targeted Therapies

Personalized medicine and targeted therapies are significantly transforming the Global Thyroid Gland Disorder Treatment Market by shifting from generalized treatment approaches to patient-specific solutions. Advancements in genetic research and molecular diagnostics have enabled healthcare providers to tailor treatments based on an individual's genetic profile, disease progression, and therapeutic response. This precision is particularly beneficial in managing thyroid disorders, where hormone imbalances and autoimmune conditions necessitate specialized strategies.

In recent years, the U.S. Food and Drug Administration (FDA) has approved several targeted therapies for thyroid cancers with specific genetic mutations. For instance, in September 2024, the FDA granted traditional approval to selpercatinib (Retevmo) for adults and pediatric patients aged 2 years and older with advanced or metastatic medullary thyroid cancer (MTC) harboring RET mutations. This approval underscores the shift towards treatments that address the molecular underpinnings of thyroid malignancies.

Key Market Players

• Abbvie Inc.
• Amgen Inc.
• GSK Plc
• Merck KGaA
• Viatris Inc.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Elexis Inc.
• IBSA Pharma (IBSA Group)

Report Scope:

In this report, the Global Thyroid Gland Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Thyroid Gland Disorder Treatment Market, By Indication:

• Hypothyroidism
• Hyperthyroidism

Thyroid Gland Disorder Treatment Market, By Route of Administration:

• Oral
• Intravenous
• Others

Thyroid Gland Disorder Treatment Market, By Distribution Channel:

• Wholesaler/Distributors
• Retail Chain
• Online Distribution
• Others

Thyroid Gland Disorder Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Thyroid Gland Disorder Treatment Market.

Available Customizations:

Global Thyroid Gland Disorder Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Thyroid Gland Disorder Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Hypothyroidism, Hyperthyroidism)
  • 5.2.2. By Route of Administration (Oral, Intravenous, Others)
  • 5.2.3. By Distribution Channel (Wholesaler/Distributors, Retail Chain, Online Distribution, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Thyroid Gland Disorder Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Thyroid Gland Disorder Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Thyroid Gland Disorder Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Thyroid Gland Disorder Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Thyroid Gland Disorder Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Thyroid Gland Disorder Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Thyroid Gland Disorder Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Thyroid Gland Disorder Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Thyroid Gland Disorder Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Thyroid Gland Disorder Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Thyroid Gland Disorder Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Thyroid Gland Disorder Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Thyroid Gland Disorder Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Thyroid Gland Disorder Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Thyroid Gland Disorder Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Thyroid Gland Disorder Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Distribution Channel

9. South America Thyroid Gland Disorder Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Thyroid Gland Disorder Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Thyroid Gland Disorder Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Thyroid Gland Disorder Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Thyroid Gland Disorder Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Thyroid Gland Disorder Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Thyroid Gland Disorder Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Thyroid Gland Disorder Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Abbvie Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Amgen Inc.
• 14.3. GSK Plc
• 14.4. Merck KGaA
• 14.5. Viatris Inc.
• 14.6. Novartis AG
• 14.7. Pfizer Inc.
• 14.8. Takeda Pharmaceutical Company Limited
• 14.9. Elexis Inc.
• 14.10. IBSA Pharma (IBSA Group)

15. Strategic Recommendations

16. About Us & Disclaimer